NeoBase™ 2 Non-derivatized MSMS Kit – A Modern Newborn Screening Solution for Maternal and Infant HealthcareIntroduction
Introduction
In the biomedical field, newborn screening plays a crucial role in the early detection of inborn metabolic disorders, enabling timely interventions that significantly reduce the risks of disability and mortality. In Vietnam, SISC is the official distributor of the NeoBase™ 2 Non-derivatized MSMS Kit by Revvity, providing hospitals and diagnostic centers with a modern, accurate, and efficient newborn screening solution.
What is Newborn Screening?
Newborn screening is a vital public health program that utilizes advanced diagnostic techniques to detect severe congenital diseases such as metabolic disorders, endocrine disorders, and genetic abnormalities before any clinical symptoms appear. Early detection and intervention during the "golden window" give infants the opportunity for healthy development while minimizing long-term complications. Newborn screening has become a widely adopted healthcare initiative across numerous countries, including Vietnam.
Inborn Metabolic Disorders in Newborns
Inborn metabolic disorders are a group of serious genetic conditions that disrupt the body’s ability to metabolize essential substances. Without early detection and proper treatment, these disorders can lead to severe complications, including neurological damage, developmental delays, and potentially fatal outcomes. Most metabolic disorders present no clinical signs immediately after birth, making newborn screening the essential method for early diagnosis and timely intervention.
What is NeoBase™ 2 MSMS Kit?
The NeoBase™ 2 Non-derivatized MSMS Kit is an advanced expanded newborn screening solution that can detect over 57 metabolic markers from a single dried blood spot (DBS) sample. The kit employs cutting-edge tandem mass spectrometry
(MS/MS) technology, eliminating the need for complex derivatization steps, thus simplifying the workflow, enhancing safety, and reducing processing time. It is an ideal solution for large-scale screening centers that demand high accuracy and operational efficiency.
Key Screening Markers in NeoBase™ 2
| No. | Marker Group | Detected Conditions |
| 1 | Amino acids | Amino acid metabolism disorders or elevated amino acid concentrations in blood |
| 2 | Free carnitine (C0) and acylcarnitines | Fatty acid oxidation disorders (FAO) or organic acidurias (OA) |
| 3 | Nucleosides adenosine (ADO) and 2’-deoxyadenosine (D-ADO) | Adenosine deaminase severe combined immunodeficiency (ADA-SCID) |
| 4 | C26:0 lysophosphatidylcholine (C26:0-LPC) | X-linked adrenoleukodystrophy (X-ALD) |
| 5 | Succinylacetone (SA) | Tyrosinemia Type I |
Comprehensive Screening Solution
- Product name: NeoBase™ 2 Non-derivatized MSMS Kit
- Product code: 3044-001U
- Manufacturer: Revvity
- Packaging: 960 tests/kit
- Testing principle: Tandem mass spectrometry (MS/MS) analysis without derivatization, enabling multiplex screening from a single dried blood spot.
- Application: Expanded newborn screening for over 50 inborn errors of metabolism, including amino acid disorders, organic acidurias, fatty acid oxidation disorders, and specific genetic conditions such as X-ALD and ADA-SCID.
- Required equipment:
QSight® 225MD system or compatible MS/MS platforms
Wallac DBS Puncher or Panthera-Puncher™ 9
Simplicity 3Q MD softwareTesting Workflow
Key Advantages
NeoBase™ 2 Non-derivatized MSMS Kit offers significant advantages that elevate the quality of newborn screening. The kit features a simplified and safe workflow, eliminating the need for derivatization, thereby reducing hazardous chemical exposure and enhancing laboratory safety. With a rapid extraction time of approximately 30 minutes and an enzyme incubation period of 60 minutes, the kit supports high-throughput sample processing, making it well-suited for large-scale screening laboratories.
The NeoBase™ 2 kit enables simultaneous screening of over 50 metabolic markers from a single DBS sample, optimizing both workflow efficiency and operational costs. It also significantly minimizes the risk of false-positive results, ensuring highly accurate and reliable outcomes.
Furthermore, the kit is seamlessly integrated with the QSight® 225MD system, supporting full automation and reducing reagent consumption, providing long-term cost benefits for screening centers.
Testing Workflow
1. Collect a heel-prick blood sample from the newborn on a specialized filter paper.
2. Punch the sample into a 96-well plate and add the Extraction Working Solution.
3. Extract for 30 minutes and incubate the enzyme reaction for 60 minutes.
4. Analyze the sample using an MS/MS system.
5. Rapidly generate accurate and reliable screening reports.
Why Choose NeoBase™ 2 from SISC?
SISC is the official distributor of Revvity in Vietnam, committed to providing NeoBase™ 2 Non-derivatized MSMS Kit with verified origins and comprehensive certifications. SISC offers a full-service solution, including product supply, equipment, reagents, and specialized operator training.
Our experienced technical team is always ready to provide on-site support, technical consultation, and prompt troubleshooting assistance throughout system operation.
The newborn screening workflow with NeoBase™ 2 at SISC is optimized for speed, efficiency, and exceptional accuracy, fully meeting the demands of large-scale screening centers and hospitals across the country.
Conclusion
The NeoBase™ 2 Non-derivatized MSMS Kit represents a comprehensive, modern, and highly reliable newborn screening solution for healthcare providers and laboratories in Vietnam. This kit enables early detection of life-threatening metabolic disorders, supports timely intervention, and protects infant health from the very first days of life.
SISC is committed to accompanying and supporting our partners throughout the implementation, operation, and continuous development of high-quality newborn screening services in Vietnam.
